Neuroscience
| 4 min read
Psychedelic acquisitions, clinical trial updates, and more led the news this week.
| 3 min read
A new platform combines engineered viral vectors with the brain's glymphatic system to improve gene delivery to glial cells implicated in multiple neurological disorders.
| 3 min read
KCL-286 repaired neuronal DNA damage and reduced neuroinflammation in mice, with prior Phase 1 safety data potentially accelerating its path to Alzheimer's trials.
| 4 min read
Phase 3 trial results for neurological drugs, an AI platform for central nervous system drug discovery, a novel long-acting flu antiviral, and more led the news this week.
| 3 min read
Some people with amyloid plaques and tau tangles in their brain never develop Alzheimer’s disease. New research suggests it comes down to microglial activity.
Advanced microelectrode array and liquid handling technologies make neuronal culture screening more consistent and easier to scale.
| 5 min read
A first-in-class synaptic regenerative approach shows promise across multiple neurodegenerative and neuropsychiatric diseases.
| 3 min read
Using an unbiased molecular screen, researchers found a new gene that could be targeted to treat fragile X syndrome.
| 3 min read
It’s long been recognized that obesity in midlife significantly raises the risk of Alzheimer’s disease. A new study shows the biological mechanisms that contribute to pathogenesis.
| 6 min read
The compound reduced opioid intake within hours in rats and was linked to changes in synaptic organization and gene expression in reward-related brain regions.
| 4 min read
Researchers have identified a distinctive gut microbiome pattern linked to Parkinson’s disease that appears in both diagnosed patients and a subset of symptom-free individuals who may already be on a disease trajectory.
| 6 min read
Emerging data shows alpha synuclein may be present in the majority of neurodegenerative disease cases, reshaping how clinicians understand dementia and Parkinson’s.
